Compare MXE & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MXE | ACXP |
|---|---|---|
| Founded | 1990 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.2M | 6.8M |
| IPO Year | N/A | 2021 |
| Metric | MXE | ACXP |
|---|---|---|
| Price | $12.35 | $3.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $143.67 |
| AVG Volume (30 Days) | 5.8K | ★ 78.8K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 2.66% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.40 | $3.17 |
| 52 Week High | $11.51 | $25.00 |
| Indicator | MXE | ACXP |
|---|---|---|
| Relative Strength Index (RSI) | 62.80 | 41.07 |
| Support Level | $11.91 | $3.98 |
| Resistance Level | $12.40 | $3.63 |
| Average True Range (ATR) | 0.24 | 0.33 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 74.36 | 22.92 |
Mexico Equity and Income Fund Inc. is a closed-end, non-diversified management investment company that aims for long-term capital appreciation and current income. It prominently invests in equity, convertible securities, and debt issued by Mexican companies, operating across various sectors. The fund benchmarks its performance against the Mexbol and MSCI Mexico Index. The company provides a vehicle to investors who wish to invest in Mexican companies through a managed non-diversified portfolio as part of their overall investment program.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.